These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 37509309)

  • 41. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development of BTK resistance mutations in chronic lymphocytic leukemia.
    Joseph RE; Wales TE; Jayne S; Britton RG; Fulton DB; Engen JR; Dyer MJS; Andreotti AH
    bioRxiv; 2023 Dec; ():. PubMed ID: 38187560
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
    Wang ML; Jurczak W; Zinzani PL; Eyre TA; Cheah CY; Ujjani CS; Koh Y; Izutsu K; Gerson JN; Flinn I; Tessoulin B; Alencar AJ; Ma S; Lewis D; Lech-Maranda E; Rhodes J; Patel K; Maddocks K; Lamanna N; Wang Y; Tam CS; Munir T; Nagai H; Hernandez-Ilizaliturri F; Kumar A; Fenske TS; Seymour JF; Zelenetz AD; Nair B; Tsai DE; Balbas M; Walgren RA; Abada P; Wang C; Zhao J; Mato AR; Shah NN
    J Clin Oncol; 2023 Aug; 41(24):3988-3997. PubMed ID: 37192437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.
    Zygmunciak P; Robak T; Puła B
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Next-Generation Sequencing-Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).
    Simon F; Bohn JP
    Curr Oncol Rep; 2023 Oct; 25(10):1181-1189. PubMed ID: 37682487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
    Miao Y; Xu W; Li J
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
    Isaac K; Mato AR
    Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
    Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
    Front Immunol; 2021; 12():766272. PubMed ID: 34912339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia:
    Quartermaine C; Ghazi SM; Yasin A; Awan FT; Fradley M; Wiczer T; Kalathoor S; Ferdousi M; Krishan S; Habib A; Shaaban A; Kola-Kehinde O; Kittai AS; Rogers KA; Grever M; Ruz P; Bhat S; Dickerson T; Byrd JC; Woyach J; Addison D
    JACC CardioOncol; 2023 Oct; 5(5):570-590. PubMed ID: 37969643
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Approved and emerging Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Hatashima A; Karami M; Shadman M
    Expert Opin Pharmacother; 2022 Sep; 23(13):1545-1557. PubMed ID: 35973973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
    Naeem A; Utro F; Wang Q; Cha J; Vihinen M; Martindale S; Zhou Y; Ren Y; Tyekucheva S; Kim AS; Fernandes SM; Saksena G; Rhrissorrakrai K; Levovitz C; Danysh BP; Slowik K; Jacobs RA; Davids MS; Lederer JA; Zain R; Smith CIE; Leshchiner I; Parida L; Getz G; Brown JR
    Blood Adv; 2023 May; 7(9):1929-1943. PubMed ID: 36287227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Egyed M; Lueff S; Borbely J; Illes A
    Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists.
    Nixon S; Duquette D; Doucette S; Larouche JF
    Curr Oncol; 2023 Apr; 30(4):4222-4245. PubMed ID: 37185435
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
    Bose P; Gandhi VV; Keating MJ
    Expert Opin Drug Metab Toxicol; 2016 Nov; 12(11):1381-1392. PubMed ID: 27686109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.